Abstract：Stereotactic body radiation therapy has become more and more popular in clinical practice due to its satisfactory efficacy and relatively low incidence of side effects. Different fractionation schemes are adopted based on the characteristics, location, and size of tumor. However, the optimal fractionation scheme and dose limits for organs at risk are still not clear. Therefore, further studies and observation of long-term adverse reactions are required.
Xiao Guangli. Current status of clinical application of stereotactic body radiation therapy[J]. Chinese Journal of Radiation Oncology, 2016, 25(9): 1015-1019.
[1] Chang JY,De Ruysscher D.Individualized hypo/hyperfractionated radiotherapy for non-small cell lung cancer[J].J Thorac Dis,2014,6(4):285-286.DOI:10.3978/j.issn.2072-1439.2013.12.47. [2] Onishi H,Shirato H,Nagata Y,et al. Stereotactic body radiotherapy (SBRT) for operable stage Ⅰ non-small-cell lung cancer:can SBRT be comparable to surgery[J].Int J Radiat Oncol Biol Phys,2011,81(5):1352-1358.DOI:10.1016/j.ijrobp.2009.07.1751. [3] Chang JY,Li QQ,Xu QY,et al. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer:how to fly in a “no fly zone”[J].Int J Radiat Oncol Biol Phys,2014,88(5):1120-1128.DOI:10.1016/j.ijrobp.2014.01.022. [4] Taremi M,Hope A,Dahele M,et al. Stereotactic body radiotherapy for medically inoperable lung cancer:prospective,single-center study of 108 consecutive patients[J].Int J Radiat Oncol Biol Phys,2012,82(2):967-973.DOI:10.1016/j.ijrobp.2010.12.039. [5] Nuyttens JJ,van der Voort van Zyp NC,Praag J,et al. Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors[J].Radiother Oncol,2012,102(3):383-387.DOI:10.1016/j.radonc.2011.12.023. [6] Stanic S,Paulus R,Timmerman RD,et al. No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early-stage peripheral non-small cell lung cancer:an analysis of RTOG 0236[J].Int J Radiat Oncol Biol Phys,2014,88(5):1092-1099.DOI:10.1016/j.ijrobp.2013.12.050. [7] Henderson M,McGarry R,Yiannoutsos C,et al. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage Ⅰ non-small-cell lung cancer[J].Int J Radiat Oncol Biol Phys,2008,72(2):404-409.DOI:10.1016/j.ijrobp.2007.12.051. [8] Haasbeek CJA,Lagerwaard FJ,de Jaeger K,et al. Outcomes of stereotactic radiotherapy for a new clinical stage Ⅰ lung cancer arising postpneumonectomy[J].Cancer,2009,115(3):587-594.DOI:10.1002/cncr.24068. [9] Ishihara T,Yamada K,Tanahashi H,et al. Stereotactic body radiation therapy for lung cancer in octogenarians[J].Int J Radiat Oncol Biol Phys,2012,84(3S):S550-S551.DOI:10.1016/j.ijrobp.2012.07.1468. [10] Crabtree TD,Denlinger CE,Meyers BF,et al. Stereotactic body radiation therapy versus surgical resection for stage Ⅰ non-small cell lung cancer[J].J Thorac Cardiovasc Surg,2010,140(2):377-386.DOI:10.1016/j.jtcvs.2009.12.054. [11] Zhang BL,Zhu FP,Ma XL,et al. Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer:a systematic review and meta-analysis[J].Radiother Oncol,2014,112(2):250-255.DOI:10.1016/j.radonc.2014.08.031. [12] Grills IS,Mangona VS,Welsh R,et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage Ⅰ non-small-cell lung cancer[J].J Clin Oncol,2010,28(6):928-935.DOI:10.1200/JCO.2009.25.0928. [13] Chang JY,Senan S,Paul MA,et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage Ⅰ non-small-cell lung cancer:a pooled analysis of two randomised trials[J].Lancet Oncol,2015,16(6):630-637.DOI:10.1016/S1470-2045(15)70168-3. [14] Baschnagel AM,Mangona VS,Robertson JM,et al. Lung metastases treated with image-guided stereotactic body radiation therapy[J].Clin Oncol,2013,25(4):236-241.DOI:10.1016/j.clon.2012.12.005. [15] Okunieff P,Petersen AL,Philip A,et al. Stereotactic body radiation therapy (SBRT) for lung metastases[J].Acta Oncol,2006,45(7):808-817.DOI:10.1080/02841860600908954. [16] Dhakal S,Corbin KS,Milano MT,et al. Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas:excellent local lesion control and improved patient survival[J].Int J Radiat Oncol Biol Phys,2012,82(2):940-945.DOI:10.1016/j.ijrobp.2010.11.052. [17] Tremosini S,Reig M,de Lope CR,et al. Treatment of early hepatocellular carcinoma:towards personalized therapy[J].Dig Liver Dis,2010,42(S3):S242-S248.DOI:10.1016/S1590-8658(10)60512-9. [18] Yoon SM,Lim YS,Park MJ,et al. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma[J].PLoS One,2013,8(11):e79854.DOI:10.1371/journal.pone.0079854. [19] Kwon JH,Bae SH,Kim JY,et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer[J].BMC Cancer,2010,10(1):475.DOI:10.1186/1471-2407-10-475. [20] Katz AW,Chawla S,Qu ZH,et al. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma:clinical outcome and pathologic correlation[J].Int J Radiat Oncol Biol Phys,2012,83(3):895-900.DOI:10.1016/j.ijrobp.2011.08.032. [21] O’Connor JK,Trotter J,Davis GL,et al. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation[J].Liver Transpl,2012,18(8):949-954.DOI:10.1002/lt.23439. [22] Kang JK,Kim MS,Cho CK,et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization[J].Cancer,2012,118(21):5424-5431.DOI:10.1002/cncr.27533. [23] Yamashita H,Onishi H,Matsumoto Y,et al. Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients[J].Radiat Oncol,2014,9(1):112.DOI:10.1186/1748-717X-9-112. [24] Xi M,Zhang L,Zhao L,et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis[J].PLoS One,2013,8(5):e63864.DOI:10.1371/journal.pone.0063864. [25] Rusthoven KE,Kavanagh BD,Cardenes H,et al. Multi-institutional phase Ⅰ/Ⅱ trial of stereotactic body radiation therapy for liver metastases[J].J Clin Oncol,2009,27(10):1572-1578.DOI:10.1200/JCO.2008.19.6329. [26] Jang WI,Kim MS,Bae SH,et al. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma[J].Radiat Oncol,2013,8(1):250.DOI:10.1186/1748-717X-8-250. [27] Chang DT,Shaffer J,Pollom E,et al. Pooled analysis of liver stereotactic body radiation therapy for hepatocellular carcinoma:results from a multi-institution study[J].Int J Radiat Oncol Biol Phys,2014,90(1S):S376.DOI:10.1016/j.ijrobp.2014.05.1211. [28] Boda-Heggemann J,Dinter D,Weiss C,et al. Hypofractionated image-guided breath-hold SABR (Stereotactic Ablative Body Radiotherapy) of liver metastases-clinical results[J].Radiat Oncol,2012,7(1):92.DOI:10.1186/1748-717X-7-92. [29] Son SH,Choi BO,Ryu MR,et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma:dose-volumetric parameters predicting the hepatic complication[J].Int J Radiat Oncol Biol Phys,2010,78(4):1073-1080.DOI:10.1016/j.ijrobp.2009.09.009. [30] King CR,Freeman D,Kaplan I,et al. Stereotactic body radiotherapy for localized prostate cancer:pooled analysis from a multi-institutional consortium of prospective phase Ⅱ trials[J].Radiother Oncol,2013,109(2):217-221.DOI:10.1016/j.radonc.2013.08.030. [31] Katz AJ,Kang J.Stereotactic body radiotherapy as treatment for organ confined low-and intermediate-risk prostate carcinoma,a 7-year study[J].Front Oncol,2014,4:240.DOI:10.3389/fonc.2014.00240. [32] Oliai C,Lanciano R,Sprandio B,et al. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer[J].J Radiat Oncol,2013,2(1):63-70.DOI:10.1007/s13566-012-0067-2. [33] Boike TP,Lotan Y,Cho LC,et al. Phase I dose-escalation study of stereotactic body radiation therapy for low-and intermediate-risk prostate cancer[J].J Clin Oncol,2011,29(15):2020-2026.DOI:10.1200/JCO.2010.31.4377. [34] King CR,Brooks JD,Gill H,et al. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer[J].Int J Radiat Oncol Biol Phys,2012,82(2):877-882.DOI:10.1016/j.ijrobp.2010.11.054. [35] Arcangeli S,Scorsetti M,Alongi F.Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review[J].Crit Rev Oncol Hematol,2012,84(1):101-108.DOI:10.1016/j.critrevonc.2011.11.009. [36] MacDougall ND,Dean C,Muirhead R.Stereotactic body radiotherapy in prostate cancer:is rapidarc a better solution than Cyberknife?[J].Clin Oncol,2014,26(1):4-9.DOI:10.1016/j.clon.2013.08.008. [37] Henderson DR,Tree AC,van As NJ.Stereotactic body radiotherapy for prostate cancer[J].Clin Oncol,2015,27(5):270-279.DOI:10.1016/j.clon.2015.01.011. [38] Katz A,Ferrer M,Suárez JF,et al. Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer[J].Radiat Oncol,2012,7(1):194.DOI:10.1186/1748-717X-7-194. [39] King CR,Collins S,Fuller D,et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer:results from a multi-institutional consortium of prospective trials[J].Int J Radiat Oncol Biol Phys,2013,87(5):939-945.DOI:10.1016/j.ijrobp.2013.08.019. [40] Katz AJ,Kang J.Quality of life and toxicity after SBRT for organ-confined prostate cancer,a 7-year study[J].Front Oncol,2014,4:301.DOI:10.3389/fonc.2014.00301. [41] Helou J,Morton G,Zhang L,et al. Stereotactic radiation therapy versus external beam+ high-dose-rate brachytherapy boost in the treatment of localized prostate cancer:a quality of life analysis[J].Int J Radiat Oncol Biol Phys,2014,90(1 Supll):S415-S416.DOI:10.1016/j.ijrobp.2014.05.1319. [42] Evans JR,Zhao S,Daignault-Newton S,et al. Comparative effectiveness analysis of patient-reported quality of life (QOL) after stereotactic body radiation therapy as compared to intensity modulated radiation therapy or low-dose-rate brachytherapy up to 2 years after treatment[J].Int J Radiat Oncol Biol Phys,2014,90(1S):S409.DOI:10.1016/j.ijrobp.2014.05.1300. [43] Anand AK,Venkadamanickam G,Punnakal AU,et al. Hypofractionated stereotactic body radiotherapy in spinal metastasis-with or without epidural extension[J].Clin Oncol,2015,27(6):345-352.DOI:10.1016/j.clon.2015.01.035. [44] Garg AK,Shiu AS,Yang J,et al. Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases[J].Cancer,2012,118(20):5069-5077.DOI:10.1002/cncr.27530. [45] Gerszten PC,Burton SA,Ozhasoglu C,et al. Radiosurgery for spinal metastases:clinical experience in 500 cases from a single institution[J].Spine,2007,32(2):193-199.DOI:10.1097/01.brs.0000251863.76595.a2. [46] Hall WA,Stapleford LJ,Hadjipanayis CG,et al. Stereotactic body radiosurgery for spinal metastatic disease:an evidence-based review[J].Int J Surg Oncol,2011,2011:979214.DOI:10.1155/2011/979214. [47] Heron DE,Rajagopalan MS,Stone B,et al. Single-session and multisession cyberknife radiosurgery for spine metastases-university of pittsburgh and georgetown university experience[J].J Neurosurg Spine,2012,17(1):11-18.DOI:10.3171/2012.4.SPINE11902. [48] Lee SH,Lee KC,Choi J,et al. Clinical applicability of biologically effective dose calculation for spinal cord in fractionated spine stereotactic body radiation therapy[J].Radiol Oncol,2015,49(2):185-191.DOI:10.1515/raon-2015-0008. [49] Ryu S,Jin JY,Jin R,et al. Partial volume tolerance of the spinal cord and complications of single-dose radiosurgery[J].Cancer,2007,109(3):628-636.DOI:10.1002/cncr.22442. [50] Sahgal A,Ma LJ,Weinberg V,et al. Reirradiation human spinal cord tolerance for stereotactic body radiotherapy[J].Int J Rad Oncol Biol Phy,2012,82(1):107-116.DOI:10.1016/j.ijrobp.2010.08.021.
2016, Vol. 25 
